# Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults

> **NCT03239483** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 28 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Dapivirine gel
- **DRUG:** Placebo gel

## Key facts

- **NCT ID:** NCT03239483
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-26
- **Primary completion:** 2018-09-20
- **Final completion:** 2018-09-20
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2021-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03239483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03239483, "Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03239483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*